Proposal to improve IMDRF adverse events exchange program imminent
This article was originally published in Clinica
The International Medical Device Regulators Forum is revamping its initiative that enables regulators around the world to exchange confidential information on serious adverse events (SAEs) for medical devices.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.